Shares of surged 7.61 per cent in Monday's trade to hit a high of Rs 1,464.70 after the company announced a partnership with Novo Nordisk India to launch Poviztra, a semaglutide injection (2.4 mg) for weight management in India.

Under the agreement, Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing of Poviztra across the country. The collaboration aims to strengthen the distribution and availability of semaglutide for chronic weight management, particularly through pharmacies and in regions beyond those currently served by Novo Nordisk India. Advertisement

Poviztra is a second brand of Wegovy (semaglutide injection 2.4 mg), which Novo Nordisk launched in India in June 2025. Wegovy is indicated as an adjunct to a reduced-calorie diet and

See Full Page